Tiziana Life Sciences announced that a late‑breaking poster on its Phase 2a intranasal foralumab study in Multiple System Atrophy (MSA) has been accepted for presentation at the 7th World Parkinson Congress in Phoenix, Arizona, scheduled for May 24‑27 2026.
The poster, titled “A Phase 2a Study of Intranasal Foralumab in Multiple System Atrophy,” will present the design and rationale of the ongoing TILS‑025 trial (NCT06868628). The trial is a six‑month, open‑label study that began dosing in August 2025 and was actively recruiting as of September 17 2025.
Foralumab is a fully human anti‑CD3 monoclonal antibody delivered intranasally to stimulate regulatory T cells and modulate neuroinflammation without systemic immune suppression. The TILS‑025 trial is the first clinical investigation of an intranasal anti‑CD3 therapy in MSA, a rare neurodegenerative disease with no approved disease‑modifying treatments.
The acceptance of the poster marks a significant milestone for Tiziana’s intranasal platform, providing an opportunity to showcase early‑stage data to the Parkinson’s and MSA research community and to attract interest from potential partners or investors focused on neuroinflammatory therapeutics. The company is also exploring intranasal foralumab in other neurodegenerative indications, including non‑active secondary progressive multiple sclerosis, mild Alzheimer’s disease, and amyotrophic lateral sclerosis.
The 7th World Parkinson Congress will bring together researchers, clinicians, and advocates from around the world, and the presentation of the TILS‑025 poster will position Tiziana to engage key opinion leaders and potentially accelerate collaboration or funding opportunities for its intranasal platform.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.